From the Research
N-acetylcysteine (NAC) is not the most effective option for lowering Gamma-Glutamyltransferase (GGT) levels, as the most recent and highest quality study suggests that Ursodeoxycholic Acid (UDCA) is more effective in reducing GGT levels in patients with nonalcoholic fatty liver disease (NAFLD) 1. The study published in 2024, found that UDCA significantly reduced GGT levels (p ≤ 0.0001) in NAFLD patients, making it a more effective option for lowering GGT levels compared to NAC. Some key points to consider when using UDCA to lower GGT levels include:
- Typical dosing ranges for UDCA are around 13-15 mg/kg/day, often administered for several months
- UDCA works by improving liver function and reducing oxidative stress in the liver
- UDCA is generally well-tolerated, with mild gastrointestinal symptoms being the most common side effects
- Individual responses to UDCA may vary, and it should be used as part of a comprehensive approach to addressing underlying causes of elevated GGT, such as reducing alcohol consumption, improving diet, and managing conditions like diabetes or obesity It's essential to consult with a healthcare provider before starting UDCA, especially for those taking other medications or with existing health conditions. While NAC may have some benefits in reducing oxidative stress and improving liver function, the most recent and highest quality evidence suggests that UDCA is a more effective option for lowering GGT levels in patients with NAFLD 1.